---
figid: PMC10915323__ajcr0014-0407-f1
pmcid: PMC10915323
image_filename: ajcr0014-0407-f1.jpg
figure_link: /pmc/articles/PMC10915323/figure/fig01/
number: Figure 1
figure_title: ''
caption: The major signaling pathways of molecular targeted drugs. FL, FLT-3 ligand;
  FLT-3, FMS-like tyrosine kinase-3; GDNF, glial cell-derived neurotrophic factor;
  GFRα, GDNF family receptor α; RET, rearranged during transfection; HGF, hepatocyte
  growth factor; MET, mesenchymal-epithelial transition factor; SCF, stem cell factor;
  c-KIT, proto-oncogene proteins c-kit; EGF, epidermal growth factor; EGFR, epidermal
  growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular
  endothelial growth factor receptor; PDGF, platelet-derived growth factor; PDGFR,
  platelet-derived growth factor receptor; FGF, fibroblast growth factor; FGFR, fibroblast
  growth factor receptor; PI3K (phosphatidylinositol-3 kinase)/AKT/mammalian target
  of rapamycin (mTOR) signaling pathway; RAS/RAF/MEK/ERK signaling pathway.
article_title: Leveraging molecular targeted drugs and immune checkpoint inhibitors
  treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.
citation: Jing-Yang Su, et al. Am J Cancer Res. 2024;14(2):407-428.
year: '2024'

doi: 10.62347/EJAA3388
journal_title: American Journal of Cancer Research
journal_nlm_ta: Am J Cancer Res
publisher_name: e-Century Publishing Corporation

keywords:
- Thyroid carcinoma
- sodium iodide symporter
- tyrosine kinase inhibitors
- immune checkpoint inhibitors
- redifferentiation

---
